juvenile idiopathic arthritis
Rheumatology · 2011–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Immune-mediated inflammatory diseases (IMIDs) in paediatric patients, including juvenile idiopathic arthritis, Crohn disease, ulcerative colitis, psoriasis,… | Jul 2025 | Deferred | 6 individuals |
| etanercept General Schedule Authority Required and Section 100 (Highly Specialised Drugs Program) Authority Required listings for severe psoriatic arthritis, ankylosing… | Jul 2025 | Recommended with restriction | none received |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| tofacitinib Treatment of severe active juvenile idiopathic arthritis (JIA) in patients aged 2-17 years with polyarticular course JIA in whom an adequate response has not… | Mar 2023 | Recommended with restriction | 11 individuals Australian Rheumatology Association · Arthritis Australia · Musculoskeletal Australia · Creaky Joints Australia · Juvenile Arthritis Foundation Australia · Pain Australia |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2021 | Recommended | unclear |
| etanercept Biosimilar to Enbrel for severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile… | Nov 2021 | Recommended with restriction | unclear |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Treatment of severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's disease, moderate… | Jul 2018 | Recommended with restriction | none received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile severe chronic plaque… | Mar 2018 | Recommended with restriction | none received |
| etanercept Biosimilar etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended with restriction | input received |
| etanercept Treatment of severe active juvenile idiopathic arthritis in patients under 18 years of age who weigh 62.5 kg or greater, presented as a higher-strength… | Jul 2014 | Recommended with restriction | no section in document |
| abatacept Treatment of severe active juvenile idiopathic arthritis (JIA) in patients who have severe intolerance of, or toxicity due to methotrexate or who have failed… | Jul 2011 | Not recommended | no section in document |
Who spoke
Colitis Australia · Australian Rheumatology Association · Arthritis Australia · Musculoskeletal Australia · Creaky Joints Australia · Juvenile Arthritis Foundation Australia · Pain Australia
What the PBS pays
$412M in government benefit over 2024–25, across 589,041 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
| etanercept | $79.8M |
| tofacitinib | $57.8M |
| Abatacept | $32.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| sarilumabSarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) | TA1104 | terminated | 2025-10 |
| baricitinibBaricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | terminated | 2024-06 |
| tofacitinibTofacitinib for treating juvenile idiopathic arthritis | TA735 | recommended restricted | 2021-10 |
| abatacept adalimumab etanercept and tocilizumabAbatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | recommended | 2015-12 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 16 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.